# David Z.I. Cherney

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-z-i-cherney/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,261 |
| Field | Diabetes Treatment and Management |
| h-index | 79 |
| i10-index | 307 |
| Last Known Institution | University Health Network |
| OpenAlex ID | https://openalex.org/A5029467844 |
| ORCID iD | 0000-0003-4164-0429 |
| Works | 561 |

## Researcher papers

Showing 12 of 26.

- [Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes](https://scholariq.org/papers/cardiovascular-outcomes-with-ertugliflozin-in-type-2-diabetes/)
- [Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus](https://scholariq.org/papers/sodium-glucose-cotransporter-2-inhibitors-in-the-treatment-of-diabetes-mellitus/)
- [Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus](https://scholariq.org/papers/renal-hemodynamic-effect-of-sodium-glucose-cotransporter-2-inhibition-in/)
- [Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes](https://scholariq.org/papers/association-of-sglt2-inhibitors-with-cardiovascular-and-kidney-outcomes-in/)
- [Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease/)
- [Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials](https://scholariq.org/papers/impact-of-diabetes-on-the-effects-of-sodium-glucose-co-transporter-2-inhibitors/)
- [The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus](https://scholariq.org/papers/the-effect-of-empagliflozin-on-arterial-stiffness-and-heart-rate-variability-in/)
- [Sodium Glucose Cotransporter-2 Inhibition in Heart Failure](https://scholariq.org/papers/sodium-glucose-cotransporter-2-inhibition-in-heart-failure/)
- [Renoprotective effects of sodium-glucose cotransporter-2 inhibitors](https://scholariq.org/papers/renoprotective-effects-of-sodium-glucose-cotransporter-2-inhibitors/)
- [Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial](https://scholariq.org/papers/effects-of-empagliflozin-on-the-urinary-albumin-to-creatinine-ratio-in-patients/)
- [Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes](https://scholariq.org/papers/serum-urate-lowering-with-allopurinol-and-kidney-function-in-type-1-diabetes/)
- [Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials](https://scholariq.org/papers/empagliflozin-as-adjunctive-to-insulin-therapy-in-type-1-diabetes-the-ease/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Diabetes and associated disorders](https://scholariq.org/topics/diabetes-and-associated-disorders/)

## Researcher university

- [University Health Network](https://scholariq.org/institutions/university-health-network/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.